Dramatic Response of Rapid Progressive Atypical Pyoderma Gangrenosum to Infliximab in a Patient with Ulcerative Colitis
| Author | Reza Fatemi | en |
| Author | Farahnaz Safaei | en |
| Author | Pardis Ketabi Moghadam | en |
| Author | Peyman Taheri | en |
| Orcid | Pardis Ketabi Moghadam [0000-0001-7110-2950] | en |
| Issued Date | 2022-12-31 | en |
| Abstract | Pyoderma gangrenosum (PG) is a relatively uncommon disorder associated with autoimmune and inflammatory conditions, including inflammatory bowel disease (IBD). PG’s prevalence ranges from 0.4 - 2.6% in patients with IBD. We describe a 34-year-old man with ulcerative colitis (UC) who was referred to our center with some small follicular and pustular lesions rapidly progressing into a painful necrotic ulcer in the right axilla. The ulcer was not responsive to broad spectrum antibiotics and topical cytotoxic agents like tacrolimus. Finally, a dramatic response was observed after initiating anti-tumor necrosis factor (anti-TNF) treatment with infliximab (10 mg/kg) within a week. A significant reduction in size and necrotic tissue was achieved one month after the index date of the prescription of infliximab. A 2-month follow-up of the patient revealed complete healing of the lesion. | en |
| DOI | https://doi.org/10.5812/jssc-131970 | en |
| URI | https://brieflands.com/journals/jssc/articles/131970 | en |
| Keyword | Pyoderma Gangrenosum | en |
| Keyword | Inflammatory Bowel Disease | en |
| Keyword | Ulcerative Colitis | en |
| Keyword | Infliximab | en |
| Publisher | Brieflands | en |
| Title | Dramatic Response of Rapid Progressive Atypical Pyoderma Gangrenosum to Infliximab in a Patient with Ulcerative Colitis | en |
| Type | Case Report | en |